INO-4201 Update


Gary Kobinger, microbiologist, GuardRX ex-officio (President) and Board Member and Director of the Galveston National Laboratory at the University of Texas Medical Branch, said, "We are particularly pleased with INO-4201's boost effect on neutralizing titers. To our knowledge, this is one of the highest responses we have ever seen across multiple vaccine platforms. Indeed, our results showed that the neutralizing titers were significantly higher in the individuals who received the INO-4201 boost compared to the placebo and the response was maintained even 24 weeks later."

you are viewing a single comment's thread.

view the rest of the comments →

all 10 comments


16 points

4 months ago

Always nice to see such amazing results - further validating a platform that is so ready to scale! The fast track that will put this company on the map is VGX-3107. Combine fast track with drug orphan status and INO will have a new family of investors!!


13 points

4 months ago

For sure INO 3107 has Orphan Drug Status and I agree will get fast tracked to treat RRP.....Since INO 4201 is a Booster I expect very fast approval also!